Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy
| Autor: | Satoshi Nagamori, Kazuhiro Nagao, Masashi Murakumo, Haruo Seki, Nobuo Shinohara, Toru Harabayashi, Takayoshi Demura, Katsuya Nonomura, Kimiyoshi Mitsuhashi, Hideyasu Matsuyama, Katsusuke Naito, Shin Suzuki |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Urologic Neoplasms Cancer Research medicine.medical_specialty Organoplatinum Compounds Paclitaxel medicine.medical_treatment Urology Phases of clinical research Neutropenia Toxicology Disease-Free Survival Drug Administration Schedule chemistry.chemical_compound Antineoplastic Combined Chemotherapy Protocols Humans Medicine Pharmacology (medical) Nedaplatin Ifosfamide Aged Salvage Therapy Pharmacology Chemotherapy business.industry Combination chemotherapy Middle Aged medicine.disease Nitrogen mustard Surgery Regimen Treatment Outcome Oncology chemistry Female Cisplatin Neoplasm Recurrence Local business medicine.drug |
| Zdroj: | Cancer Chemotherapy and Pharmacology. 58:402-407 |
| ISSN: | 1432-0843 0344-5704 |
| DOI: | 10.1007/s00280-005-0175-4 |
| Popis: | Background and aims: The aim of the present phase II study was to evaluate the efficacy of combination chemotherapy of paclitaxel, ifosfamide, and nedaplatin (PIN regimen) in patients with recurrent urothelial cancer who had been treated with cisplatin-based chemotherapy. Patients/methods: Eligible patients were those with histologically confirmed urothelial cancer who had progressed or relapsed after cisplatin-based chemotherapy. The PIN regimen consisted of paclitaxel 175 mg/m2 on day 1; ifosfamide 4.5 g/m2 divided over days 1, 2, and 3; and nedaplatin 70 mg/m2 on day 1; PIN was given every 28 days. Results: Among the 32 patients enrolled in the study (median age, 66 years), complete and partial responses were obtained in 5 patients and 19 patients, respectively, with an overall response rate of 75% (95% confidence interval [CI], 59–91%). The median time to progression was 8 months (range, 0–50+ months) and the median survival was 22 months (range, 4–52+ months). The 1- and 2-year overall survival rates were 53.7 and 42.9%, respectively. All patients experienced Grade 3 or 4 neutropenia, while Grade 3 or 4 thrombocytopenia was seen in 8 patients; Grade 3 or 4 anemia was seen in 6 patients; Grade 3 neuropathy was observed in 1 patient, for whom the PIN therapy was discontinued. There were no treatment-related deaths. Conclusion: The PIN combination was highly active and tolerable in previously treated patients with urothelial cancer as a second-line treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink